Armata Pharmaceuticals, Inc.
ARMP
$1.91
-$0.10-4.98%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 14.24% | 34.92% | -10.71% | -7.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 14.24% | 34.92% | -10.71% | -7.28% |
| Cost of Revenue | -2.61% | -0.56% | 80.00% | 38.02% | 34.56% |
| Gross Profit | 2.89% | 2.01% | -87.76% | -44.43% | -41.29% |
| SG&A Expenses | 7.88% | 13.17% | 26.84% | 61.99% | 53.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.41% | 4.83% | 2.74% | 3.82% | -0.26% |
| Operating Income | -1.58% | -3.78% | 0.39% | -5.34% | -0.65% |
| Income Before Tax | 99.46% | 72.60% | 30.50% | -81.37% | -86.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.46% | 72.60% | 30.50% | -81.37% | -86.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.46% | 72.60% | 30.50% | -81.37% | -86.65% |
| EBIT | -1.58% | -3.78% | 0.39% | -5.34% | -0.65% |
| EBITDA | -0.78% | -2.99% | 1.17% | -4.91% | -0.24% |
| EPS Basic | 99.47% | 72.63% | 30.58% | -81.14% | -86.31% |
| Normalized Basic EPS | -18.40% | -20.79% | -16.27% | -22.34% | -11.31% |
| EPS Diluted | 50.76% | 18.60% | 4.82% | -113.94% | -91.13% |
| Normalized Diluted EPS | 9.29% | -4.36% | -12.67% | -19.03% | -2.51% |
| Average Basic Shares Outstanding | 0.22% | 0.24% | 0.22% | 0.19% | 0.18% |
| Average Diluted Shares Outstanding | 29.19% | 15.08% | 1.17% | 1.15% | 14.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |